Organon & Co. Reports Earnings Results, Falls Short of Estimates

Organon & Co. (NYSE:OGN - Get Free Report) released its quarterly earnings report on Thursday, showcasing an earnings per share (EPS) of $0.83. This figure fell short of the analysts' consensus estimate of $0.92 by $0.09, as reported by Zacks. Notably, the company achieved a net margin of 20.30% and an impressive return on equity of 644.70%.

In addition to reporting earnings, Organon & Co. also revised its guidance for the fiscal year 2025, indicating future expectations for EPS.

Stock Performance

On the day of the earnings announcement, Organon & Co. stock experienced a notable increase, rising 8.6%. During trading hours, the stock price gained $1.27, reaching $15.97. The trading volume on that day was reported at 6,160,096 shares, significantly higher than the average trading volume of 2,694,525 shares. The company's financial metrics include a quick ratio of 1.21, a current ratio of 1.70, and a debt-to-equity ratio of 17.73. Organon & Co. holds a market capitalization of approximately $4.11 billion and possesses a PE ratio of 3.17, along with a price-to-earnings growth ratio of 0.83. Over the past year, the stock has hit a low of $13.87 and a high of $23.10, with a 50-day moving average of $15.33 and a 200-day moving average of $17.54.

Analyst Ratings and Outlook

In the realm of investment analysis, TD Cowen updated its rating for Organon & Co. to a "hold" in a research note published on January 15th. Current assessment from investment analysts shows varied opinions, with one analyst assigning a sell rating, two designating a hold rating, one indicating a buy, and another giving a strong buy rating. This leads to an average rating of "hold" for Organon & Co. on MarketBeat.com, along with a consensus target price set at $21.33.

About Organon & Co.

Organon & Co. is a global pharmaceutical company focused on delivering innovative health solutions. It emphasizes a portfolio encompassing prescription therapies in women's health, biosimilars, and established brands. Founded on March 11, 2020, the company is headquartered in Jersey City, NJ.

Future investment considerations may include the recommendations from top analysts and the company's ongoing performance in the health sector.

Earnings, Stocks, Analysis